NO20083240L - Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia - Google Patents

Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia

Info

Publication number
NO20083240L
NO20083240L NO20083240A NO20083240A NO20083240L NO 20083240 L NO20083240 L NO 20083240L NO 20083240 A NO20083240 A NO 20083240A NO 20083240 A NO20083240 A NO 20083240A NO 20083240 L NO20083240 L NO 20083240L
Authority
NO
Norway
Prior art keywords
compositions
methods
treatment
swine
cachexia
Prior art date
Application number
NO20083240A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Kenley
Jonas Ekblom
Mikhail Denissenko
Original Assignee
Anaborex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaborex Inc filed Critical Anaborex Inc
Publication of NO20083240L publication Critical patent/NO20083240L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20083240A 2005-12-22 2008-07-22 Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia NO20083240L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75311805P 2005-12-22 2005-12-22
US77275206P 2006-02-13 2006-02-13
PCT/IB2006/004315 WO2008093148A2 (en) 2005-12-22 2006-12-20 Compositions and methods for prevention and treatment of cachexia

Publications (1)

Publication Number Publication Date
NO20083240L true NO20083240L (no) 2008-09-22

Family

ID=38194678

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083240A NO20083240L (no) 2005-12-22 2008-07-22 Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia

Country Status (6)

Country Link
US (1) US8080528B2 (enExample)
EP (1) EP1991270A4 (enExample)
JP (1) JP2009526087A (enExample)
MX (1) MX2008007790A (enExample)
NO (1) NO20083240L (enExample)
WO (1) WO2008093148A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021509A2 (en) * 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2155180B1 (en) * 2007-04-24 2016-07-13 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
ES2721753T3 (es) 2007-05-21 2019-08-05 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090221518A1 (en) * 2007-11-18 2009-09-03 Anaborex, Inc. Compositions and Methods for Treatment of Exudative Serous Effusion
US8257684B2 (en) * 2008-03-26 2012-09-04 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
JP5620918B2 (ja) * 2008-11-25 2014-11-05 ブリストル・マイヤーズ スクイブ カンパニー アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2012009542A2 (en) * 2010-07-14 2012-01-19 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
WO2020018554A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Methods of treating renal disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859782A (en) * 1986-06-26 1989-08-22 Harbor Branch Oceanographic Institution, Inc. Misakinolide compositions and their derivatives
EP0662324A1 (en) 1987-09-15 1995-07-12 The Rowett Research Institute Use of beta-adrenergic agonists for treating loss of function of striated muscles
HUT50044A (en) 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
US5252564A (en) * 1991-03-29 1993-10-12 The United States Of America As Represented By The Secretary Of Agriculture Method to decrease cortisol secretion by feeding melengesterol acetate
CA2194049A1 (en) * 1994-06-28 1996-01-11 Georgi Stankov Novel clinical uses of polyene macrolides
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
WO2008004224A2 (en) 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders

Also Published As

Publication number Publication date
US20070149465A1 (en) 2007-06-28
EP1991270A4 (en) 2009-12-02
WO2008093148A3 (en) 2009-04-16
EP1991270A2 (en) 2008-11-19
JP2009526087A (ja) 2009-07-16
MX2008007790A (es) 2009-03-04
WO2008093148A2 (en) 2008-08-07
US8080528B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
WO2007095497A3 (en) Compositions and methods for prevention and treatment of cachexia
CY1113055T1 (el) Μεθοδοι θεραπειας δερματικης εξαψης χρησιμοποιωντας εκλεκτικους αγωνιστες αλφα-2-αδρενεργικου υποδοχεα
DK1948155T3 (da) Farmaceutiske præparater omfattende droxidopa
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
GT200600160A (es) Tratamiento del dolor
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA200970338A2 (ru) Агонисты рецептора еро человека, композиции, способы и применение для предотвращения или лечения состояний, связанных с интолерантностью к глюкозе
DK1893213T3 (da) Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme
EA202190678A1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
EA201990365A1 (ru) Лечение и предотвращение расстройств сна

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application